CFRX a great risks/reward ratio! 🧙ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases.
If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
Biotech
MRNA going back to $120, entered downard channel trend!MRNA seems to have entered another downward channel trend.
Using the previous resistance on the last downward channel trend we can see it can act as a sort of support, the trend also made two other downward resistances as you can see on the chart.
This makes me to believe that this could go back down to $120 where it can make a double bottom which can be a great buying opportunity, but for now, I'm bearish.
AQB is on the watchlistAquaBounty (AQB) NASDAQ:AQB
AquaBounty is a company that deals currently in aquaculture services, specializing in the farming of bioengineered Atlantic salmon that can grow to market size faster than what the conventional market offers.
The appeal in ABQ is clear. As global natural salmon production decreases due to environmental constraints put upon by climate change and pollution, aquaculture of salmonids is already used to meet market demands at a competitive price. Bioengineered salmon is reportedly faster to produce and more efficient; therefore, following conventional logic, bioengineering salmon is the logical next step for a competitive market to meet increasing demands.
Their product is known as the: Aquadvantage Salmon
Cathie Wood from ARK invest has backed this and they currently own 12.18%/ 8,640,421 shares.
The Vanguard Group also have a stake of 2.09% with Blackrock trailing behind at 0.82%
My only concern is the public perception of GMO foods. As reported by The Hartman Group, consumer perception of GMO foods is increasingly negative year by year.
Chains such as Costco have refused to serve these GMO salmons which may pose a potential risk for ABQ in the short term.
But long term we will have to continue modifying organisms in order to reach a point of sustainability.
Looking at the chart we could retest 10$ again easily before Earnings. Due to the fact, their patented product hasn't yet arrived in the US, it could crash back after if it doesn't beat estimate EPS.
Then again, it is FDA approved so hopefully, it will take the market by storm when things open up again in the summer.
If it drops to the 5$ range I will open a long position. If it consolidates at 7-8$ I may reconsider.
(Disclaimer not financial advice just opinion)
BIIB has incoming Golden Cross, rising past support zone?Hi. In this 1D chart I've marked an impending Golden Cross: the point where a MA 56 is very likely to cross a MA 224 upwards.
With this I've also plotted out a Resistance zone and a Support zone. The price has just entered the Resistance zone but instead of turning back this time the momentum of the Golden Cross should push it past the Resistance zone.
I've also included two example trades. One has its SL placed on the price of the Golden Cross and then given a ratio of two to make a reasonable TP.
The other has its SL placed on the top line of the Support zone and given a ratio of 1.75 to make a more conservative long position and keep the TP within a reasonable price.
Thank you. Please, if you have any thoughts or comments do leave them below and I would gladly discuss or adjust my interpretations and methods with you.
This does not constitute financial advice. Any projected prices, even if explicitly stated, are made with intent to discuss the symbol and potential interpretations. Any trades shown or mentioned are examples and neither recommendations or mandates.
BNGO round 2!!!!This play looks tempting ngl. NASDAQ:BNGO
Bionanon made very tasty returns so why not return. Price is near 0+/- ATR in keltner and if it closes above I will enter.
Last time I entered around $5 and avg'ED up till $5.6.
Took Profit around $14 but this chart looks promising.
Genomics is still an underrated sector and there are many supporters of its hot product -' The Saphyre system'
Let's see how this runs. Good luck
Entry - $7-$8 since it bottomed at $6.90. Set trailing SL of 15%.
TP - $9-$10, since it might test resistance and bounce back down. Great company but burns through cash, so some major hyped event would need to occur for it to retest ATH.
(Disclaimer this is not financial advice just my opinion)
Anti-aging biotech is looking super juicy meow meow style!I don't invest in Pharma, and this isn't Pharma! As I understand it, the company is making implants to help counter the aging process. Very future, very cool!
I think this could be a very good week for this stock!
As always, this is not investment advice!
MRNA jumps after hitting support, whats next?For this analysis, I am going to be using the same downward trend channel that I made on March 25th and it went exactly as expected. This recent spike might be coming to an end though due to being overbought on the RSI and close to hitting the resistance on the trend channel.
Although if it breaks through that resistance it can become support, keep an eye on MRNA. If it doesn't break through then it could go back to the $120s level.
MVMD — Target of shoddy short hit piece by anonymous SA authorThis is a very similar setup to my earlier EXRO call where an anonymous author calling him/herself “Mariner Research Group” put together a shoddy “short thesis” that was quite frankly garbage. It would not surprise me if this “Night Research Group” is the exact same person. Same quality of work, same hastily put together WordPress website with no contact info other than email and no names of who is behind it. Same terrible track record where none of the previous price targets have been reached. Same low follower count.
From the technical perspective, MVMD is oversold on the hourly and is approaching oversold territory on the daily chart . .95 gap was filled and support was found at the .96 Fibonacci line. If support holds, it will start forming a bullish Double Bottom pattern. There’s also a gap at 1.10 up above. Decent risk/reward but stop loss is not a bad idea, IMO.
MRNA broke through support (Next target $110?)I published multiple bearish analyses on MRNA since 145$, right now it broke through the support at $120 and if it doesnt recover today then it's most likely going to go to $110-$100.
Although if that doesn't hold it can go down to $75.
ARKG - Long term viewARKG looks like a double bounce at the bottom of thee channel, which is also the 0.382 retracement of the wave 4. Probably a little bit more channeling here before we get going.
If we get a reversal here, wave 5 should bring us to anywhere between 145-160 by EoY
Recognized R&D Pioneers in Anti-Inflammatory TherapeuticsThe founding team members at 180 Life Sciences Corp. (NASDAQ: ATNF) are the recognized pioneers of research and development in anti-inflammatory therapeutics.
180 Life Sciences is a clinical-stage biotechnology company that brings together the expertise of world-renowned scientists to develop and test novel treatments for inflammation and is currently working in both preclinical and clinical studies.
finance.yahoo.com
DNLI a long-term add over 53.50This is not a commentary on the promising fundamentals or potential of Denali Therapeutics but rather a purely technical analysis. DNLI has been consolidating in a falling wedge pattern coming off a nice run up from August of 2020. Price seems to have found a recent bottom at the all-time 50% fib as well a s the 200ema. These are critical levels to hold but so long as it does a bounce out of this wedge pattern seems likely.
HGEN: Weekend Before Phase III DataHGEN has two RCTs with imminent data, one of them the company's own, the other the NIH's ACTIV-5 Trial. The company is preparing to file an EUA for Lenzilumab pending the trials' completion. Announcements are expected in the week starting March 29, two days from now. Nomis Bay, a fund that had held a large stake of HGEN since it was trading in single digits unloaded millions of shares in the weeks leading up to now. The fund still holds between 9% and 10% of the outstanding shares.In conferences throughout March, HGEN executives mainly showcased the potential for Lenz as a COVID therapeutic, and differences between their trial designs and those of other, failed monoclonal antibodies. I hope everyone is sized appropriately, whether long or short. This stock could make some very large moves soon.
$OI to join S&P SmallCap 600 on March 30Neurocrine Biosciences Inc. (NASD:NBIX) will replace O-I Glass Inc. (NYSE:OI) in the S&P MidCap 400, and O-I Glass will replace HMS Holdings Corp (NASD:HMSY) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, March 30.
finance.yahoo.com
$APOP and Quoin Pharmaceuticals Announce Strategic MergerCellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger
Up to $25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the merger
Cellect shareholders to retain 25% of the combined Company pre-funding
Quoin has secured $25 million in committed equity funding from Altium Capital, a highly regarded institutional healthcare investor.
Quoin has also negotiated an $18.5 million venture loan from a leading U.S. commercial bank.
Completion of the merger is subject to approval of the Cellect and Quoin shareholders and certain other conditions and is expected to close by the end of the second quarter of 2021.
Why $IMMP soared in December case studyFirst time an antigen presenting cell (APC) activator has shown an Overall Survival (OS) benefit in a randomised setting in metastatic breast cancer patients known to be insensitive to immune checkpoint inhibitor therapy
Promising and improving overall trend in OS in total population (based on approx. 60% of events): median survival benefit of +2.7 months from efti plus chemotherapy, compared to chemotherapy plus placebo.
Statistically significant OS benefit in efti group observed in pre-defined patient groups:
+7.1 months survival benefit (median of 21.9 vs. 14.8 months, nearly 50% longer) from efti with chemotherapy for patients under 65 years of age
+9.4 months survival benefit (median of 22.4 vs. 12.9 months, 74% longer) from efti with chemotherapy for patients with a low starting monocyte count
Statistically significant increase in CD8 T cells in patients treated with efti plus chemotherapy, correlated with prolonged OS, indicating pharmacodynamic activity and proof of concept of efti’s mode of action
Collection of OS data ongoing, with final data expected to be reported mid 2021
finance.yahoo.com
$PRQR Announces Positive Results from Clinical Trial of QR-421aProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials.
QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)
QR-421a observed to be well tolerated with no serious adverse events reported
Two pivotal Phase 2/3 trials are expected to start by the end of 2021
finance.yahoo.com
MNDR - Downtrend channelModerna is clearly in a downtrend channel and I wouldn't be surprised if it hits $120. I have long positions opened at $139 so I will sell those tomorrow and buy back lower.
APOP Cellect Biotechnology Upside PotentialNext time when you see those upside spikes is a chart, that is and extremely bullish sign. Maybe some insider buys!
Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology that enables the functional selection of stem cells, and Quoin Pharmaceuticals Inc. (“Quoin”), a privately held specialty pharmaceutical company, today announced that the Boards of Directors of the two companies have unanimously approved a definitive Merger Agreement. (globenewswire.com)
Market Cap of only 13.644M. This still has room to grow!
If you are interested to test some amazing BUY and SELL INDICATORS which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
$HOTH Announces Positive Data from Animal TestingVoltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19
today announced positive data from its second set of preclinical animal testing of its HaloVax™ Self-Assembling Vaccine (SAV) against COVID-19.
finance.yahoo.com
$bntc Skyrocket as Morgan Stanley Takes StakeBenitec Shares Skyrocket as Morgan Stanley Takes Stake
$BNTC shares blasted higher Tuesday after disclosing in a regulatory filing that Morgan Stanley has a 5.2% stake in the genetic drug company.
The stake amounts to 249,174 shares, or about $1.51 million.
Benitec‘s “proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration,” the company said.
“The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD), and Chronic Hepatitis B.”
www.thestreet.com
BNTC Benitech Biopharma we bought the dipMorgan Stanley disclosed in an SEC filing that it had increased its stake in the company by around 5.2%!
Don`t worry, it has still upside potential, despite the 130% increase in the Pre-Market.
Market Cap of only 15.37M
This is a 5X stock, Not trading advice as you know! :)
This was a private call from my trading group and one of my top picks for March.
You can check the transcripts here:
www.patreon.com
If you are also interested to test some amazing BUY and SELL INDICATORS that i use, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
